This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Frontier Biotechnologies Co., Ltd

Drug Names(s): AB 001, AB-001

Description: AB-001 is a non-hydrogel based transdermal patch formulation of an NSAID for the treatment of acute pain and inflammation of the joints and muscles.

Deal Structure: Frontier and ABsize
In November 2014, Nanjing Frontier Biotechnologies announced the acquisition of global rights to a novel topical patch for acute and chronic pain management from ABsize of Japan.

AB001 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug